Disrupting Protein Production in Tumors: A Novel Immunotherapy Strategy
A groundbreaking study led by researchers at the University of Liège’s GIGA Institute has revealed a fresh approach to stimulate the immune system against cancer. By subtly disrupting the way tumor cells manufacture proteins, scientists have triggered a potent antitumor immune response in preclinical models, potentially transforming “cold” tumors – those unresponsive to traditional immunotherapy – into those susceptible to immune attack.
How Cancer Cells Evade Immunity
All cells rely on a precise protein production system guided by genetic instructions. This process utilizes molecular adaptors called transfer RNAs (tRNAs) to ensure proteins are built correctly. Cancer cells exploit this system to maintain stability and avoid triggering immune responses. The research, recently accepted for publication in Nature Communications, highlights the crucial role of a specific tRNA modification, controlled by an enzyme called KEOPS, in helping melanoma tumors evade immune detection.
The Role of tRNA Modification and KEOPS
The study found that disrupting this tRNA modification leads to the production of misfolded proteins that accumulate inside cancer cells. “By disrupting this quality-control mechanism, we force the tumor to reveal what it normally works hard to hide,” explains Pierre Close, Director of the Laboratory of Cancer Signaling at the GIGA Institute. “This buildup of faulty proteins acts as a warning signal: it triggers an immune response similar to the one activated during viral infections. It’s an entirely new way of activating antitumor immunity.”
Activating the Immune System
This buildup of misfolded proteins activates an innate immune sensor typically used to detect viral infections. This, in turn, attracts and activates immune T cells, which infiltrate the tumor and drive its rejection. In preclinical models, blocking this pathway transformed “cold” tumors into “hot” tumors, demonstrating markedly reduced growth.
A New Strategy for Resistant Tumors
Immunotherapies have revolutionized cancer treatment, but many tumors remain resistant. This research presents a fundamentally new approach: instead of directly stimulating immune cells, researchers can render tumor cells more susceptible to antitumor immunity by altering how they produce proteins. “Our work shows that the stability of protein production can turn into a true Achilles’ heel for tumors,” says Cléa Dziagwa, Télévie PhD candidate and first author of the publication. “Understanding how tRNAs influence immune evasion opens the possibility of intervening where conventional immunotherapies fail.”
Future Directions and Translational Potential
The research, conducted in collaboration with international partners in the UK and Germany, and supported by FNRS and WELRI/WELBIO, strengthens Belgium’s position in RNA biology and cancer immunology. Researchers hope to translate these discoveries into new therapeutic strategies for difficult-to-treat cancers. By understanding how tumors control their internal protein machinery to escape immune detection, they aim to design interventions that re-engage the immune system and improve patient outcomes.
this study underscores the idea that making cancer vulnerable isn’t always about directly attacking it, but about revealing it to the immune system.